These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 28992560)

  • 1. Effectiveness and tolerability of Perampanel in children, adolescents and young adults with refractory epilepsy: A UK national multicentre study.
    Swiderska N; Tan HJ; Rajai A; Silwal A; Desurkar A; Martland T
    Seizure; 2017 Nov; 52():63-70. PubMed ID: 28992560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies-An Italian observational multicenter study.
    De Liso P; Vigevano F; Specchio N; De Palma L; Bonanni P; Osanni E; Coppola G; Parisi P; Grosso S; Verrotti A; Spalice A; Nicita F; Zamponi N; Siliquini S; Giordano L; Martelli P; Guerrini R; Rosati A; Ilvento L; Belcastro V; Striano P; Vari MS; Capovilla G; Beccaria F; Bruni O; Luchetti A; Gobbi G; Russo A; Pruna D; Tozzi AE; Cusmai R
    Epilepsy Res; 2016 Nov; 127():93-100. PubMed ID: 27568598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical profiles associated with serum perampanel concentrations in children with refractory epilepsy.
    Ishikawa N; Tateishi Y; Tani H; Kobayashi Y; Kobayashi M
    Epilepsy Behav; 2019 May; 94():82-86. PubMed ID: 30897534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability and efficacy of perampanel in children with refractory epilepsy.
    Heyman E; Lahat E; Levin N; Epstein O; Lazinger M; Berkovitch M; Gandelman-Marton R
    Dev Med Child Neurol; 2017 Apr; 59(4):441-444. PubMed ID: 27935018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical experience with adjunctive perampanel in adult patients with uncontrolled epilepsy: A UK and Ireland multicentre study.
    Shah E; Reuber M; Goulding P; Flynn C; Delanty N; Kemp S
    Seizure; 2016 Jan; 34():1-5. PubMed ID: 26615577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study.
    Villanueva V; Garcés M; López-González FJ; Rodriguez-Osorio X; Toledo M; Salas-Puig J; González-Cuevas M; Campos D; Serratosa JM; González-Giráldez B; Mauri JA; Camacho JL; Suller A; Carreño M; Gómez JB; Montoya J; Rodríguez-Uranga J; Saiz-Diaz R; González-de la Aleja J; Castillo A; López-Trigo J; Poza JJ; Flores J; Querol R; Ojeda J; Giner P; Molins A; Esteve P; Baiges JJ
    Epilepsy Res; 2016 Oct; 126():201-10. PubMed ID: 27521586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes of perampanel vs. lacosamide in cohorts of consecutive patients with severely refractory epilepsies - A monocentric retrospective analysis of systematically collected data from the German Kork Epilepsy Center.
    Kurth C; Kockelmann E; Steinhoff BJ
    Seizure; 2017 Feb; 45():47-51. PubMed ID: 27915111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy of perampanel in young children with drug-resistant epilepsy.
    Chang FM; Fan PC; Weng WC; Chang CH; Lee WT
    Seizure; 2020 Feb; 75():82-86. PubMed ID: 31901668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perampanel as adjunctive therapy in highly refractory epilepsies: Real-world data from an Italian tertiary care epilepsy centre.
    Morano A; Fattouch J; Albini M; Casciato S; Fanella M; Basili LM; Viganò A; Manfredi M; Giallonardo AT; Di Bonaventura C
    J Neurol Sci; 2018 Jul; 390():67-74. PubMed ID: 29801910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of perampanel in children and adolescents with pharmacoresistant epilepsy: The first real-world evaluation in Asian pediatric neurology clinics.
    Lin KL; Lin JJ; Chou ML; Hung PC; Hsieh MY; Chou IJ; Lim SN; Wu T; Wang HS
    Epilepsy Behav; 2018 Aug; 85():188-194. PubMed ID: 30032806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perampanel in routine clinical use in idiopathic generalized epilepsy: The 12-month GENERAL study.
    Villanueva V; Montoya J; Castillo A; Mauri-Llerda JÁ; Giner P; López-González FJ; Piera A; Villanueva-Hernández P; Bertol V; Garcia-Escrivá A; Garcia-Peñas JJ; Garamendi I; Esteve-Belloch P; Baiges-Octavio JJ; Miró J; Falip M; Garcés M; Gómez A; Gil-López FJ; Carreño M; Rodriguez-Uranga JJ; Campos D; Bonet M; Querol R; Molins A; Tortosa D; Salas-Puig J
    Epilepsia; 2018 Sep; 59(9):1740-1752. PubMed ID: 30062784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of pooled phase III trials of adjunctive perampanel for epilepsy: Impact of mechanism of action and pharmacokinetics on clinical outcomes.
    Kwan P; Brodie MJ; Laurenza A; FitzGibbon H; Gidal BE
    Epilepsy Res; 2015 Nov; 117():117-24. PubMed ID: 26448264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of adjuvant perampanel: an Australian multicenter real-world observational study in refractory focal and generalized epilepsy syndromes.
    Sagar P; Wawryk O; Vogrin S; Whitham E; Kiley M; Frasca J; Carne R; Seneviratne U; Cook MJ; Lawn N; Nikpour A; D'Souza WJ
    Epilepsy Behav; 2021 Jun; 119():107935. PubMed ID: 33930626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study.
    Rosenfeld W; Conry J; Lagae L; Rozentals G; Yang H; Fain R; Williams B; Kumar D; Zhu J; Laurenza A
    Eur J Paediatr Neurol; 2015 Jul; 19(4):435-45. PubMed ID: 25823975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retention of perampanel in adults with pharmacoresistant epilepsy at a single tertiary care center.
    Wehner T; Mannan S; Turaga S; Vallabhaneni K; Yip HM; Wiggans C; Shankar R; Duncan JS; Sander JW
    Epilepsy Behav; 2017 Aug; 73():106-110. PubMed ID: 28624720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term tolerability, safety and efficacy of adjunctive perampanel in the open-label, dose-ascending Study 231 and extension Study 233 in Japanese patients with epilepsy.
    Usui N; Akamatsu N; Nakasato N; Ohnishi A; Kaneko S; Hiramatsu H; Saeki K; Miyagishi H; Inoue Y
    Seizure; 2018 Nov; 62():26-32. PubMed ID: 30267941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Perampanel in treatment of refractory partial epilepsy in adolescents and adults: results of international multicenter randomized, double-blind, placebo-controlled phase III studies].
    Belousova ED
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(8):32-8. PubMed ID: 25345628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study.
    Nishida T; Lee SK; Inoue Y; Saeki K; Ishikawa K; Kaneko S
    Acta Neurol Scand; 2018 Apr; 137(4):392-399. PubMed ID: 29250772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A post hoc analysis of the long-term safety and efficacy of perampanel in Asian patients with epilepsy.
    Inoue Y; Kaneko S; Hsieh PF; Meshram C; Lee SA; Aziz ZA; Nabangchang C; Dash A
    Epilepsia; 2019 Mar; 60 Suppl 1():60-67. PubMed ID: 30869167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective, multicentre study of perampanel given as monotherapy in routine clinical care in people with epilepsy.
    Gil-Nagel A; Burd S; Toledo M; Sander JW; Lebedeva A; Patten A; Laurenza A;
    Seizure; 2018 Jan; 54():61-66. PubMed ID: 29288911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.